Galapagos discovers novel class of antibiotics that kill all MRSA strains

11/27/2012 | Examiner.com

Belgian biotech firm Galapagos said it has identified a new class of antibiotics that demonstrate strong activity against drug-resistant strains of Staphylococcus aureus, including MRSA. The antibiotic acts against an enzyme that is key to the growth of all bacteria, the company said. Galapagos said clinical studies could begin for the antibiotic candidate CAM-1 in early 2014.

View Full Article in:

Examiner.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
MEDICAL SCIENCE LIAISON - 14000002RO
Abbott
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Executive Medical Director
Aspirus Network Inc
Wausau, WI